PBPIA
VIGL

Pivotal bioVenture Partners Investment Advisor’s Vigil Neuroscience VIGL Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-560,595
Closed -$4.46M – 13
2025
Q2 		$4.46M Hold
560,595
– – 2.76% 7
2025
Q1 		$998K Hold
560,595
– – 0.81% 9
2024
Q4 		$953K Hold
560,595
– – 0.64% 10
2024
Q3 		$1.91M Hold
560,595
– – 1.13% 9
2024
Q2 		$2.24M Hold
560,595
– – 1.72% 7
2024
Q1 		$1.91M Hold
560,595
– – 1.23% 9
2023
Q4 		$1.89M Hold
560,595
– – 0.48% 11
2023
Q3 		$3.02M Hold
560,595
– – 1.21% 10
2023
Q2 		$5.27M Hold
560,595
– – 1.74% 8
2023
Q1 		$5.49M Hold
560,595
– – 2.26% 8
2022
Q4 		$7.01M Hold
560,595
– – 3.05% 5
2022
Q3 		$5.1M Hold
560,595
– – 1.86% 8
2022
Q2 		$1.45M Hold
560,595
– – 0.73% 10
2022
Q1 		$3.94M Buy
+560,595
New +$7.4M 1.86% 10

Other funds holding VIGL

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's VIGL Position: Q3 2025 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 560,595 shares — an estimated $4.46M sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $7.01M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 560,595 Vigil Neuroscience shares in Q3 2025, an estimated $4.46M.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
  • Pivotal bioVenture Partners Investment Advisor's Vigil Neuroscience position peaked at $7.01M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2025, filed 13 Nov 2025.